Dr. Reddy’s Laboratories recently launched its bioequivalent generic version of Amoxil® (Amoxicillin) tablets, capsules, and oral suspension in the US market on September 17. Amoxicillin Tablets (500 mg and 875 mg), Capsules (250 mg and 500 mg), and Oral Suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) are approved by the United States Food and Drug Administration (US FDA).
The Amoxil® brand and generic tablets (875 mg) has US sales of approximately $22.2 million, while capsules had US sales of approximately $67.2 million, and oral suspension clocked US sales of approximately $89.5 million, all for the most recent 12 months ending June 2012 according to IMS Health.
EP News Bureau